S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Bausch + Lomb’s BL1332 Trial Misses Primary Endpoint

Bausch + Lomb said a Phase 2 trial of BL1332, a treatment for pain following photorefractive keratectomy, did not meet its primary endpoint: a statistically significant reduction in pain intensity 24 hours after surgery.

Bausch + Lomb’s BL1332 Trial Misses Primary Endpoint

Patients who received BL1332 showed numerically greater pain relief across the analysis 72 hours after surgery, the eye-health company said. The treatment was well tolerated.

Bausch + Lomb is completing its analysis of the data and plans to discuss the findings with the Food and Drug Administration, including potential plans for a Phase 3 trial.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!